Western Blotting (WB), Immunofluorescence (IF), Enzyme Immunoassay (EIA)
Specificity
DRAK1 antibody was raised against a peptide corresponding to amino acids near the amino terminus of human DRAK1. DRAK1 antibody has no cross responses to DRAK2, DAP or ZIP kinases.
Purification
Affinity chromatography purified via peptide column
STK17A
Reactivity: Human
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
ELISA. Western Blot: 0.5 - 1 μg/mL. A431 or MOLT4 whole cell lysate can be used as positivecontrol and an approximately 50 kDa band can be detected. Immunocytochemistry. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Buffer
PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 for DAP kinase-related apoptosis-inducing protein kinases (1). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK1 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK1 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues (1).Synonyms: DAP kinase-related apoptosis-inducing protein kinase 1, Serine/threonine-protein kinase 17A